 Elizabeth McAninch
Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypothyroidism | 12 | 2022 | 81 | 3.080 |
Why?
| | Triiodothyronine | 11 | 2022 | 113 | 2.500 |
Why?
| | Iodide Peroxidase | 12 | 2021 | 149 | 2.320 |
Why?
| | Thyroxine | 9 | 2022 | 91 | 2.110 |
Why?
| | Hormone Replacement Therapy | 6 | 2022 | 46 | 1.900 |
Why?
| | Thyroid Hormones | 5 | 2016 | 66 | 1.700 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 332 | 1.130 |
Why?
| | Homeostasis | 3 | 2015 | 110 | 1.120 |
Why?
| | Transcriptome | 3 | 2016 | 87 | 1.110 |
Why?
| | Energy Metabolism | 3 | 2014 | 82 | 1.020 |
Why?
| | Thyroid Gland | 4 | 2021 | 62 | 1.010 |
Why?
| | Thyroid Diseases | 2 | 2018 | 21 | 0.740 |
Why?
| | Adipose Tissue | 2 | 2015 | 98 | 0.650 |
Why?
| | Thyroid Nodule | 1 | 2016 | 10 | 0.620 |
Why?
| | Insulin Infusion Systems | 1 | 2016 | 3 | 0.610 |
Why?
| | Obesity | 3 | 2015 | 338 | 0.610 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 52 | 0.590 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 59 | 0.580 |
Why?
| | Oxygen Consumption | 1 | 2015 | 65 | 0.580 |
Why?
| | Pericardium | 1 | 2015 | 27 | 0.570 |
Why?
| | Mitochondria | 1 | 2015 | 91 | 0.560 |
Why?
| | Thermogenesis | 2 | 2014 | 21 | 0.550 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 150 | 0.540 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2014 | 13 | 0.530 |
Why?
| | Hypothalamus | 1 | 2014 | 14 | 0.530 |
Why?
| | Liver | 1 | 2015 | 214 | 0.510 |
Why?
| | Adipose Tissue, Brown | 1 | 2013 | 47 | 0.510 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 159 | 0.500 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 389 | 0.490 |
Why?
| | Nervous System Diseases | 1 | 2015 | 145 | 0.480 |
Why?
| | Animals | 14 | 2021 | 5312 | 0.480 |
Why?
| | Humans | 25 | 2022 | 31481 | 0.470 |
Why?
| | Signal Transduction | 2 | 2018 | 588 | 0.440 |
Why?
| | Exercise | 1 | 2016 | 454 | 0.430 |
Why?
| | Amino Acid Substitution | 3 | 2018 | 39 | 0.360 |
Why?
| | Alzheimer Disease | 2 | 2021 | 1829 | 0.340 |
Why?
| | Threonine | 2 | 2018 | 15 | 0.320 |
Why?
| | Alanine | 2 | 2018 | 19 | 0.320 |
Why?
| | Gene Frequency | 2 | 2018 | 80 | 0.320 |
Why?
| | Fatty Liver | 2 | 2018 | 40 | 0.320 |
Why?
| | Astrocytes | 3 | 2018 | 135 | 0.300 |
Why?
| | Mice | 8 | 2021 | 1894 | 0.290 |
Why?
| | Basal Metabolism | 2 | 2016 | 9 | 0.290 |
Why?
| | Hippocampus | 2 | 2018 | 295 | 0.280 |
Why?
| | Case-Control Studies | 2 | 2018 | 687 | 0.270 |
Why?
| | Dementia | 2 | 2019 | 545 | 0.250 |
Why?
| | Tissue Extracts | 1 | 2021 | 17 | 0.230 |
Why?
| | United States | 3 | 2019 | 2539 | 0.220 |
Why?
| | Male | 10 | 2021 | 17583 | 0.220 |
Why?
| | Mice, Knockout | 6 | 2021 | 399 | 0.220 |
Why?
| | Genetic Association Studies | 1 | 2021 | 90 | 0.210 |
Why?
| | Gene Expression | 2 | 2018 | 272 | 0.200 |
Why?
| | Quality of Life | 2 | 2021 | 663 | 0.190 |
Why?
| | Thyrotropin | 2 | 2016 | 45 | 0.190 |
Why?
| | Unfolded Protein Response | 1 | 2018 | 7 | 0.190 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 13 | 0.180 |
Why?
| | HEK293 Cells | 2 | 2018 | 89 | 0.180 |
Why?
| | Microarray Analysis | 2 | 2015 | 12 | 0.180 |
Why?
| | Amiodarone | 1 | 2018 | 28 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 87 | 0.180 |
Why?
| | Hospitals | 1 | 2019 | 142 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 462 | 0.170 |
Why?
| | Oxidative Stress | 2 | 2018 | 140 | 0.170 |
Why?
| | Status Epilepticus | 1 | 2018 | 49 | 0.170 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 101 | 0.170 |
Why?
| | Hypercholesterolemia | 1 | 2018 | 39 | 0.170 |
Why?
| | Quality of Health Care | 1 | 2019 | 141 | 0.170 |
Why?
| | Female | 7 | 2021 | 18253 | 0.150 |
Why?
| | Risk Assessment | 2 | 2018 | 806 | 0.150 |
Why?
| | Osteoarthritis | 1 | 2021 | 369 | 0.150 |
Why?
| | Iodine | 1 | 2016 | 7 | 0.150 |
Why?
| | Diabetes Complications | 1 | 2016 | 74 | 0.150 |
Why?
| | Blood Proteins | 1 | 2016 | 23 | 0.150 |
Why?
| | Aged | 6 | 2021 | 10295 | 0.150 |
Why?
| | Hepatocytes | 1 | 2015 | 13 | 0.150 |
Why?
| | DNA-Binding Proteins | 1 | 2018 | 264 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 46 | 0.150 |
Why?
| | History, 20th Century | 1 | 2016 | 94 | 0.150 |
Why?
| | Protein Binding | 1 | 2016 | 155 | 0.150 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 79 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2015 | 80 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 41 | 0.140 |
Why?
| | Ubiquitination | 1 | 2015 | 15 | 0.140 |
Why?
| | HeLa Cells | 1 | 2015 | 58 | 0.140 |
Why?
| | Bone Density Conservation Agents | 1 | 2014 | 13 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2015 | 29 | 0.140 |
Why?
| | Anxiety | 1 | 2016 | 162 | 0.140 |
Why?
| | Diphosphonates | 1 | 2014 | 13 | 0.140 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 40 | 0.140 |
Why?
| | Syndrome | 1 | 2015 | 105 | 0.140 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 290 | 0.140 |
Why?
| | Adult | 4 | 2021 | 9779 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2021 | 5234 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2015 | 117 | 0.130 |
Why?
| | Osteoporosis | 1 | 2014 | 74 | 0.130 |
Why?
| | Fatty Acids | 1 | 2014 | 45 | 0.130 |
Why?
| | African Americans | 2 | 2018 | 818 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2013 | 46 | 0.130 |
Why?
| | Pilot Projects | 1 | 2015 | 455 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 224 | 0.130 |
Why?
| | Patient Compliance | 1 | 2014 | 200 | 0.120 |
Why?
| | Cerebral Cortex | 1 | 2015 | 206 | 0.120 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 351 | 0.120 |
Why?
| | Brain | 2 | 2021 | 1655 | 0.120 |
Why?
| | Transcription Factors | 1 | 2013 | 180 | 0.120 |
Why?
| | Depression | 1 | 2016 | 516 | 0.110 |
Why?
| | Ion Channels | 1 | 2013 | 232 | 0.110 |
Why?
| | Models, Biological | 1 | 2013 | 428 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2014 | 385 | 0.100 |
Why?
| | Middle Aged | 3 | 2021 | 11209 | 0.090 |
Why?
| | Thyroid Function Tests | 2 | 2018 | 14 | 0.090 |
Why?
| | Prospective Studies | 2 | 2021 | 1934 | 0.060 |
Why?
| | Desiccation | 1 | 2021 | 6 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2021 | 82 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2021 | 3910 | 0.060 |
Why?
| | Placebos | 1 | 2021 | 89 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2021 | 4 | 0.050 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 3 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 12 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2021 | 12 | 0.050 |
Why?
| | Drug Combinations | 1 | 2021 | 88 | 0.050 |
Why?
| | Drug Discovery | 1 | 2021 | 24 | 0.050 |
Why?
| | Cost of Illness | 1 | 2021 | 65 | 0.050 |
Why?
| | Models, Statistical | 1 | 2021 | 144 | 0.050 |
Why?
| | Consensus | 1 | 2021 | 106 | 0.050 |
Why?
| | Bone and Bones | 1 | 2021 | 110 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2021 | 559 | 0.050 |
Why?
| | Cartilage | 1 | 2021 | 168 | 0.050 |
Why?
| | Phenotype | 1 | 2021 | 379 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 239 | 0.050 |
Why?
| | Prevalence | 1 | 2021 | 544 | 0.050 |
Why?
| | Benchmarking | 1 | 2019 | 34 | 0.050 |
Why?
| | Golgi Apparatus | 1 | 2018 | 7 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2018 | 29 | 0.050 |
Why?
| | Quality Indicators, Health Care | 1 | 2019 | 43 | 0.050 |
Why?
| | Endoplasmic Reticulum | 1 | 2018 | 43 | 0.050 |
Why?
| | Muscarinic Agonists | 1 | 2018 | 2 | 0.050 |
Why?
| | Pilocarpine | 1 | 2018 | 3 | 0.050 |
Why?
| | Cell Death | 1 | 2018 | 68 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2018 | 90 | 0.040 |
Why?
| | Amygdala | 1 | 2018 | 56 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2018 | 308 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2021 | 832 | 0.040 |
Why?
| | Hindlimb Suspension | 1 | 2016 | 3 | 0.040 |
Why?
| | Prefrontal Cortex | 1 | 2018 | 152 | 0.040 |
Why?
| | Physical Conditioning, Animal | 1 | 2016 | 12 | 0.040 |
Why?
| | Apoptosis | 1 | 2018 | 292 | 0.040 |
Why?
| | Mental Status Schedule | 1 | 2016 | 121 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 637 | 0.040 |
Why?
| | Health Surveys | 1 | 2016 | 102 | 0.040 |
Why?
| | Calorimetry, Indirect | 1 | 2015 | 8 | 0.040 |
Why?
| | Inflammation | 1 | 2018 | 360 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 76 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2015 | 63 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2015 | 77 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2015 | 27 | 0.040 |
Why?
| | Linear Models | 1 | 2016 | 276 | 0.040 |
Why?
| | Gene Deletion | 1 | 2015 | 57 | 0.040 |
Why?
| | Prognosis | 1 | 2018 | 1028 | 0.030 |
Why?
| | Neurons | 1 | 2018 | 407 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 364 | 0.030 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 45 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 183 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 71 | 0.030 |
Why?
| | Brain Diseases | 1 | 2015 | 90 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2014 | 50 | 0.030 |
Why?
| | DNA Methylation | 1 | 2015 | 168 | 0.030 |
Why?
| | Bone Density | 1 | 2014 | 141 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2014 | 71 | 0.030 |
Why?
| | Incidence | 1 | 2016 | 829 | 0.030 |
Why?
| | Eating | 1 | 2014 | 61 | 0.030 |
Why?
| | Disease Progression | 1 | 2016 | 861 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 986 | 0.030 |
Why?
| | Chicago | 1 | 2016 | 955 | 0.030 |
Why?
| | Rats | 1 | 2015 | 966 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 1452 | 0.030 |
Why?
| | Time Factors | 1 | 2016 | 1902 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2016 | 2028 | 0.030 |
Why?
| | Cognition | 1 | 2016 | 1206 | 0.020 |
Why?
|
|
McAninch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|